Clinical characteristics at presentation of 1213 patients with de novo AML
| Age, y | |
| Median | 52 |
| Range | 15-86 |
| % patients older than 60 | 36 |
| % female | 47 |
| Median WBCs, × 109/L | 18.2 |
| % patients with WBCs more than 50 × 109/L | 29 |
| % patients with WBCs more than 100 × 109/L | 12 |
| Median hemoglobin, g/dL | 9.2 |
| Median platelets, × 109/L | 57 |
| % hepatomegaly | 11 |
| % splenomegaly | 10 |
| % extramedullary leukemia | 10 |
| FAB, no. (%) | 1115 |
| M0 | 19 (2) |
| M1 | 189 (17) |
| M2 | 413 (37) |
| M3 | 18 (2) |
| M4 | 212 (19) |
| M4Eo | 47 (4) |
| M5 | 136 (12) |
| M6/M7 | 33 (3) |
| Unclassified | 48 (4) |
| % with at least grade 3 bleeding | 6 |
| % with at least grade 3 infection | 4 |
| No. of deaths in first 7 d | 25 |
| Second induction (% CR) | 349 (52) |
| Age, y | |
| Median | 52 |
| Range | 15-86 |
| % patients older than 60 | 36 |
| % female | 47 |
| Median WBCs, × 109/L | 18.2 |
| % patients with WBCs more than 50 × 109/L | 29 |
| % patients with WBCs more than 100 × 109/L | 12 |
| Median hemoglobin, g/dL | 9.2 |
| Median platelets, × 109/L | 57 |
| % hepatomegaly | 11 |
| % splenomegaly | 10 |
| % extramedullary leukemia | 10 |
| FAB, no. (%) | 1115 |
| M0 | 19 (2) |
| M1 | 189 (17) |
| M2 | 413 (37) |
| M3 | 18 (2) |
| M4 | 212 (19) |
| M4Eo | 47 (4) |
| M5 | 136 (12) |
| M6/M7 | 33 (3) |
| Unclassified | 48 (4) |
| % with at least grade 3 bleeding | 6 |
| % with at least grade 3 infection | 4 |
| No. of deaths in first 7 d | 25 |
| Second induction (% CR) | 349 (52) |